Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy BioNTech stock
Learn how to easily invest in BioNTech stock.
BioNTech SE (BNTX) is a leading biotechnology business based in the US. It opened the day at $136.50 after a previous close of $137.57. During the day the price has varied from a low of $135.51 to a high of $138.55. The latest price was $137.19 (25 minute delay). BioNTech is listed on the NASDAQ and employs 3,082 staff. All prices are listed in US Dollars.
How to buy shares in BioNTech
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BNTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
How has coronavirus impacted BioNTech's share price?
Since the stock market crash in March caused by coronavirus, BioNTech's share price has had significant positive movement.
Its last close price was $137.19, which is 76.42% up on its pre-crash value of $32.35 and 389.96% up on the lowest point reached during the March crash when the shares fell as low as $28.00.
If you had bought $1,000 worth of BioNTech shares at the start of February 2020, those shares would have been worth $1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $4.00.
BioNTech stock price (NASDAQ: BNTX)Use our graph to track the performance of BNTX stocks over time.
BioNTech shares at a glance
|52-week range||$117.08 - $369.68|
|50-day moving average||$149.55|
|200-day moving average||$163.48|
|Wall St. target price||$222.79|
|Dividend yield||$0 (1.33%)|
|Earnings per share (TTM)||$43.77|
Buy BioNTech shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy BioNTech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioNTech price performance over time
|1 week (2022-09-29)||2.69%|
|1 month (2022-09-06)||-1.00%|
|3 months (2022-07-06)||-14.36%|
|6 months (2022-04-05)||-24.13%|
|1 year (2021-10-04)||-44.88%|
|2 years (2020-10-06)||60.29%|
|3 years (2019-10-02)||N/A|
|5 years (2017-10-02)||N/A|
Is BioNTech stock undervalued or overvalued?
Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioNTech's P/E ratio
BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, BioNTech shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
BioNTech's PEG ratio
BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0449. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.4 billion.
The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$21.2 billion|
|Operating margin TTM||72.21%|
|Gross profit TTM||$16.1 billion|
|Return on assets TTM||63.12%|
|Return on equity TTM||105.3%|
|Market capitalisation||$33.2 billion|
TTM: trailing 12 months
BioNTech share dividends
Dividend payout ratio: 4.67% of net profits
Recently BioNTech has paid out, on average, around 4.67% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), BioNTech shareholders could enjoy a 1.33% return on their shares, in the form of dividend payments. In BioNTech's case, that would currently equate to about $0 per share.
While BioNTech's payout ratio might seem low, this can signify that BioNTech is investing more in its future growth.
BioNTech's most recent dividend payout was on 17 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 2 June 2022 (the "ex-dividend date").
BioNTech share price volatility
Over the last 12 months, BioNTech's shares have ranged in value from as little as $117.08 up to $369.6835. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioNTech's is 0.0348. This would suggest that BioNTech's shares are less volatile than average (for this exchange).
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc. ; Sanofi S.
Frequently asked questionsWhat percentage of BioNTech is owned by insiders or institutions?
Currently 62.967% of BioNTech shares are held by insiders and 15.183% by institutions. How many people work for BioNTech?
Latest data suggests 3,082 work at BioNTech. When does the fiscal year end for BioNTech?
BioNTech's fiscal year ends in December. Where is BioNTech based?
BioNTech's address is: An der Goldgrube 12, Mainz, Germany, 55131 What is BioNTech's ISIN number?
BioNTech's international securities identification number is: US09075V1026 What is BioNTech's CUSIP number?
BioNTech's Committee on Uniform Securities Identification Procedures number is: 09075V102
More guides on Finder
How to buy OTC stocks
Find out how to buy OTC stocks and compare brokers who offer access to OTC Markets.
Alternatives to Webull
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Best renewable energy stocks for 2022
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
The best dividend stocks for 2022
Our list of 10 dividend stocks to watch in 2022.
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Invest in FAANG stocks
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Ask an Expert